The FDA wants to take a larger role in eliminating the inequities that lead to poorer health outcomes for minorities and other underserved groups.
The agency wants ideas for new strategic priorities that can be assumed by the Food and Drug Administration’s Office of Minority Health and Health Equity, according to a Jan. 2 notice in the Federal Register. Established in 2010, the office primarily focuses on outreach and research to increase the amount of clinical trial data available on racial and ethnic minorities, strengthening the FDA’s ability to respond to minority health concerns, and improving health literacy.
The push ...